Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Viridian Therapeutics to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, dividends, valuation, earnings and risk.
Profitability
This table compares Viridian Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Viridian Therapeutics | -1,620.79% | -79.67% | -44.72% |
| Viridian Therapeutics Competitors | -12,224.09% | -202.33% | -31.23% |
Valuation & Earnings
This table compares Viridian Therapeutics and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Viridian Therapeutics | $26.31 million | -$342.60 million | -7.76 |
| Viridian Therapeutics Competitors | $768.41 million | $11.71 million | -18.32 |
Viridian Therapeutics’ peers have higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Viridian Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Viridian Therapeutics’ peers have a beta of -1.84, indicating that their average stock price is 284% less volatile than the S&P 500.
Institutional and Insider Ownership
47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.4% of Viridian Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for Viridian Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Viridian Therapeutics | 1 | 0 | 11 | 0 | 2.83 |
| Viridian Therapeutics Competitors | 9923 | 15317 | 45694 | 1603 | 2.54 |
Viridian Therapeutics currently has a consensus price target of $41.00, indicating a potential upside of 37.58%. As a group, “Biotechnology” companies have a potential upside of 131.50%. Given Viridian Therapeutics’ peers higher probable upside, analysts clearly believe Viridian Therapeutics has less favorable growth aspects than its peers.
Summary
Viridian Therapeutics peers beat Viridian Therapeutics on 7 of the 13 factors compared.
Viridian Therapeutics Company Profile
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
